One thing to note with Eli Lilly and Axiron, is the pending civil court cases around the heart attack risk. They will not want to be seen to be pushing this drug too hard until the case clears post 2017...
in my opinion these claims are baseless (and recent research generally supports)
But, until the cases clear, Eli Lilly will not want to be seen to be pushing this too hard marketing wise. The FDA is also watching this closely and it will be interesting if they ever comment on the latest research in this space...
ACR Price at posting:
66.0¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
